Drug Database
AL

aldesleukin (Recil)

✓ Approved

Zenotech · IL2RA · 重组蛋白

什么是 aldesleukin?

aldesleukin 是一种重组蛋白,由Zenotech研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Recil
公司Zenotech
药物类别重组蛋白
分子靶点IL2RA
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

aldesleukin 作用于 1 个分子靶点:

IL2RAinterleukin 2 receptor subunit alpha (IL2R, TCGFR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

aldesleukin 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Renal cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Skin cancer✓ Approved

相关研究文献

PubMedJournal of immunotherapy (Hagerstown, Md. : 1997)2026-11-12

The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients With Metastatic Melanoma.

Mooradian Meghan J MJ, Hoshida Yujin Y, Giobbie-Hurder Anita A, Clark Joseph I JI et al.

High-dose aldesleukin (HD-IL2) produces durable responses in a portion of patients with melanoma. In the modern era, HD-IL2 is a key component of tumor infiltrating lymphocyte (TIL) therapy and newer forms of IL-2 have shown promise across tumor types. The Select trial aimed to validate biomarkers of HD-IL2 responsiveness. First, we retrospectively identified a proinflammatory (Class 2) gene expression profile (GEP) associated with HD-IL2 responsiveness. Prospective biomarker discovery was then performed in patients with metastatic melanoma receiving HD-IL2 with a primary objective to validate Class 2 GEP as a predictor of efficacy. Additional analyses examined potential serum and tissue protein biomarkers. Retrospective GEP data (n=28) demonstrated a response benefit in GEP Class 2 versus Class 1 subgroup (ORR: 86% vs. 38%; P=0.0384). In the prospective cohort with GEP data (n=152), HD-IL2 resulted in an ORR of 17.7%, a median PFS of 2.4 months (95% CI: 2.1-2.8 mo) and median OS of 21.2 months (95% CI: 19.0-25.5 mo). Using gene set enrichment analysis, Class 2 GEP tumors had a higher response (21% vs. 12%; P=0.2678) and 2-year OS (37.2% vs. 22.4% P=0.1229) in comparison to Class 1 but did not meet predefined levels of significance. Serum proteomic analysis highlighted that low C-reactive protein was associated with response. In conclusion, although Class 2 GEP did not meet the predefined measure of significance, it correlated with response and lower CRP levels were associated with improved outcomes. Building on this work, future biomarker studies are primed to guide contemporary IL-2 administration.

PMID 43019066
阅读全文 →
PubMedPloS one2026-10-29

Identification of prognostic biomarkers for nasopharyngeal carcinoma through microRNA‑mRNA network analysis combined with screening of immune‑related genes.

He Lihe L, Huang Xuan X, Huang Ping P

Nasopharyngeal carcinoma (NPC) is a common head and neck cancer, and radiotherapy is its main treatment. Recurrence and metastasis are the main causes of treatment failure. Although immunotherapy can prolong patient survival, the molecular mechanisms underlying NPC development and progression remain unclear. MicroRNAs (miRNAs) and their target genes are abnormally expressed in many tumors and are closely involved in tumor development. Therefore, this study aimed to identify key miRNAs and immune-related target genes in NPC, construct miRNA-mRNA regulatory networks, and screen for and validate core immune genes to identify prognostic molecular biomarkers for NPC. We downloaded NPC-related miRNA (GSE32960) and mRNA (GSE12452, GSE13597, GSE64634) microarray datasets from the Gene Expression Omnibus (GEO) and identified differentially expressed miRNAs (DEMs) and mRNAs (DEGs) using R. Target genes of DEMs were predicted with TargetScan, miRDB, and miRWalk, and then intersected with DEGs to identify core genes. A miRNA-mRNA regulatory network was constructed in Cytoscape. The core genes were further overlapped with immune-related gene sets, followed by functional enrichment analysis. A prognostic risk model was established using LASSO-Cox regression, and immune cell infiltration was evaluated with CIBERSORT. Model validation, immunohistochemical analysis, and drug-gene interaction analysis were also performed. In vitro, RT-qPCR was conducted in C666-1 and NP69 cell lines to verify the expression of key genes. We identified 213 potential target genes of key miRNAs. Three miRNAs (hsa-miR-30e-5p, hsa-miR-30a-5p, and hsa-miR-20a-5p) were associated with NPC prognosis, and 17 core immune-related genes were enriched in cytokine-mediated signaling, chemokine response, and JAK-STAT pathways. Five genes (CXCL11, SOCS1, ROBO1, LGR5, and RORB) showed promising diagnostic value for NPC; their expression was positively correlated (P < 0.05) with CD8 ⁺ T-cell, macrophage, and neutrophil infiltration. Drug-gene analysis predicted that 5-fluorouracil targeted LGR5 and aldesleukin targeted SOCS1. RT-qPCR demonstrated that SOCS1 was upregulated approximately 3.7-fold in NPC cells (P < 0.01). This study identified potential novel key genes in nasopharyngeal carcinoma, providing new therapeutic targets for the treatment of this disease.

PMID 42955997
阅读全文 →
PubMedThe Journal of clinical investigation2026-09-29

Receptor-tuned IL-2 mutein decouples Treg expansion from ILC2-driven cutaneous inflammation.

Sahoo Anupama A, Moorman Cody C, Tsenkova Mina M, Jing Yi Y et al.

Low-dose IL-2 and IL-2 muteins are being developed to expand Tregs for autoimmune disease therapy, but injection site reactions (ISRs) remain frequent and poorly understood. Here, we showed that IL2Mut24, a murine surrogate of IL-2 receptor α-biased (IL-2Rα-biased, IL-2Rα is also known as CD25) IL-2 mutein, enhanced Treg expansion and yet paradoxically exacerbated cutaneous inflammation compared with WT IL-2. Using immunodeficient mice, antibody blockade, and adoptive transfer, we identified group 2 innate lymphoid cells (ILC2s) as key drivers of IL-2-induced skin inflammation, defining a CD25-dependent innate activation axis that constrains immune tolerance. In cynomolgus monkeys, the CD25-biased IL-2 mutein efavaleukin alfa promoted greater peripheral Treg expansion than aldesleukin (recombinant human IL-2) but was accompanied by transient increases in IL-5 and dose-dependent ISRs, indicating conservation of this innate inflammatory program across species. To improve the therapeutic window, we engineered receptor clamps by linking IL2Mut24 to antibodies against CD25 to restrict IL-2 access to CD25. This receptor-tuned IL-2 preserved Treg selectivity, suppressed ISRs, and outperformed IL2Mut24 in experimental autoimmune encephalomyelitis by restraining Th17 responses. These findings revealed a conserved innate mechanism underlying IL-2-associated toxicity and establish receptor tuning as a strategy to improve the safety and efficacy of IL-2-based immunotherapy.

PMID 42809620
阅读全文 →
PubMedInternational journal of clinical oncology2026-07-23

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.

Nitani Chika C, Hara Junichi J, Kawamoto Hiroshi H, Taguchi Tomoaki T et al.

Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of a regimen containing granulocyte colony-stimulating factor (G-CSF)/teceleukin (regimen A) to that with GM-CSF/aldesleukin/isotretinoin (regimen B) in children with newly diagnosed high-risk neuroblastoma. After completing initial therapy including high-dose chemotherapy followed by autologous stem cell transplantation and radiotherapy, children with non-progressive disease were randomized to regimen A or B. Regimen B was identical to the immunotherapy regimen tested in ANBL0032 (six cycles of isotretinoin and five concomitant cycles of dinutuximab alternating with GM-CSF and aldesleukin). Regimen A consisted of six cycles of dinutuximab alternating with G-CSF and teceleukin. Event-free survival (EFS) and overall survival (OS) were compared between two regimens. In total, 35 patients (16 receiving regimen A and 19 receiving regimen B) were enrolled. The 2-year EFS was 80.8% for patients receiving regimen A and 62.3% for those receiving regimen B, and their OS rates were 93.8% and 100.0%, respectively. The hazard ratio of regimen A compared to regimen B for EFS was 0.494 (upper limit of one-sided 70% confidence interval: 0.710), suggesting comparable efficacy of the two regimens. Frequently recorded grade 3/4 adverse events were fever, infection, and hematologic toxicity with no obvious difference in incidence between the regimens. Our results suggest that the efficacy of the alternative regimen containing G-CSF is comparable to that of the ANBL0032 regimen, providing a rationale for further evaluation in a phase III trial.

PMID 42490004
阅读全文 →
PubMedSkin appendage disorders2025-12-18

Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine.

Gaumond Simonetta I SI, Opstal Madisyn M, Kamholtz Isabella I, Jimenez Joaquin J JJ

Alopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss, with limited treatment options for severe disease. Although Janus kinase inhibitors have recently been approved, safety concerns remain, highlighting the need for alternative targeted therapies. Biologics that modulate immune cell activity may offer novel therapeutic avenues in AA. A review of peer-reviewed case reports, case series, and clinical trials evaluating immune cell-targeting biologics for AA, including rituximab, abatacept, alefacept, efalizumab, nivolumab, aldesleukin. Rituximab (anti-CD20) achieved complete remission in 1 patient with alopecia universalis. Abatacept (CTLA4-Ig) reduced mean SALT score by 71% in responders, though no response occurred in patients with extensive disease. Alefacept (anti-CD2 fusion) showed no significant improvement over placebo in a clinical trial, yet case reports documented up to 100% regrowth. Efalizumab (anti-CD11a) failed to improve SALT in a phase II trial, but individual cases achieved 70-100% regrowth. Nivolumab (PD-1 inhibitor) produced complete regrowth maintained beyond 1 year in a single case. Aldesleukin (low-dose IL-2) did not yield statistically significant efficacy in a clinical trial; however, a pilot study reported all patients experiencing hair regrowth along with improvements in quality of life. Across studies, adverse events were mild, with no serious events reported. (1) Biologics targeting B and T cells demonstrated moderate efficacy overall, suggesting that B-cell depletion and T-cell modulation may be viable strategies in AA, although better targets are needed to improve efficacy. (2) Abatacept showed partial regrowth in multiple patients, while alefacept, efalizumab, and aldesleukin were largely ineffective in controlled trials, despite several case-level responses. (3) Rituximab and nivolumab achieved complete regrowth in isolated cases, but evidence remains anecdotal.

PMID 41409530
阅读全文 →
PubMedEuropean journal of nuclear medicine and molecular imaging2025-07-01

[68Ga]Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects.

Signore Alberto A, Galli Filippo F, Varani Michela M, Campagna Giuseppe G et al.

This study aimed to develop a ready-to-use kit for 68Ga-labelling of interleukin-2 (IL2) facilitating PET imaging of activated T-lymphocytes. Human recombinant IL2 (hrIL2) and Aldesleukin (desIL2), conjugated with two different chelators (NODAGA and THP) were compared. Conjugated-IL2 was stored, freeze-dried at -80 °C and radiolabelled at room temperature. In vitro quality controls (iTLC, HPLC, SDS-PAGE, spectrometry and binding assays on activated T-lymphocytes) and in vivo biodistribution studies in BALB/c mice, were performed. The shelf life of the lyophilized kits was assessed up to 6 months of storage, by iTLC, HPLC and SDS-PAGE. First-in-human study was conducted in 5 volunteers by performing [68Ga]Ga-THP-desIL2 PET/CT acquisitions at several time-points, to assess biodistribution and dosimetry. Mass spectrometry showed that only one molecule of THP or NODAGA is bound to N-terminus of both IL2 proteins. The most efficient conjugation was observed for THP-desIL2. [68Ga]Ga-THP-desIL2 showed higher labelling yield (LY) (59.13 ± 2.58%), radiochemical purity (RCP) (97.91 ± 0.45%) and binding affinity to its receptor on activated T-cells (Kd = 0.584 nM/L) and a more favorable biodistribution in pre-clinical studies, with rapid kidney metabolism and lower liver uptake than [68Ga]Ga-NODAGA-desIL2 and [68Ga]Ga-THP-hrIL2. Lyophilized kit of THP-desIL2 remained stable at -80 °C up to 6 months maintaining high RCP and LY. Phase I study showed a rapid plasma clearance, renal metabolism, safety and favorable dosimetry. We developed an efficient lyophilized kit of THP-desIL2 for 68Ga-labelling at room temperature in GMP conditions, obtaining excellent in vitro and in vivo results. [68Ga]Ga-THP-desIL2 PET/CT studies in humans showed favorable dosimetry and safety, thus highlighting its potential for a wide range of clinical applications, particularly in immune-mediated diseases and cancer.

PMID 40590904
阅读全文 →

注册免费账户还可查看另外 110 篇文献

免费注册查看全部文献 →

了解更多aldesleukin